Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy

被引:27
作者
Rubis, Pawel [1 ]
Wisniowska-Smialek, Sylwia [1 ]
Wypasek, Ewa [2 ]
Biernacka-Fijalkowska, Barbara [1 ]
Rudnicka-Sosin, Lucyna [3 ]
Dziewiecka, Ewa [4 ]
Faltyn, Patrycja [4 ]
Khachatryan, Lusine [4 ]
Karabinowska, Aleksandra [4 ]
Kozanecki, Artur [1 ]
Tomkiewicz-Pajak, Lidia [1 ,4 ]
Podolec, Piotr [1 ,4 ]
机构
[1] John Paul 2 Hosp, Dept Cardiac & Vasc Dis, Pradnicka St 80, PL-31202 Krakow, Poland
[2] John Paul 2 Hosp, Dept Mol Biol, Pradnicka St 80, Krakow, Poland
[3] John Paul 2 Hosp, Dept Pathol, Pradnicka St 80, PL-31202 Krakow, Poland
[4] Jagiellonian Univ, Coll Med, St Ann St 12, PL-31008 Krakow, Poland
关键词
Dilated cardiomyopathy; Extracellular matrix; Fibrosis; Markers; Collagen; Biopsy; HEART-FAILURE PATIENTS; MYOCARDIAL FIBROSIS; EUROPEAN-SOCIETY; ASSOCIATION; SERUM; MATRIX-METALLOPROTEINASE-9; METALLOPROTEINASES; EXPRESSION; PROGNOSIS; CYTOKINES;
D O I
10.1007/s00011-016-0977-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Fibrosis of extracellular matrix (ECM) in dilated cardiomyopathy (DCM) corresponds to the myocardial over-production of various types of collagens. However, mechanism of this process is poorly understood. To investigate whether enhanced metabolism of ECM occur in DCM. Seventy consecutive DCM patients (pts) (48 +/- A 12.1 years, EF 24.4 +/- A 7.4 %) and 20 healthy volunteers were studied. Based on symptoms duration, pts were divided into new-onset (n = 35, 6 months) and chronic DCM (n = 35, > 6 months). Markers of collagen type I and III synthesis-procollagen type I carboxy- and amino-terminal peptides (PICP and PINP) and procollagen type III carboxy- and amino-terminal peptides (PIIICP and PIIINP), collagen 1 (col-1), ECM metabolism controlling factors-tumor growth factor beta-1 (TGF1-beta), connective tissue growth factor (CTGF), and ECM degradation enzymes-matrix metalloproteinases (MMP-2, MMP-9) and their tissue inhibitor (TIMP-1) were measured in serum. All pts underwent right ventricular endomyocardial biopsy to study ECM fibrosis. The presence of fibrosis was detected in 24 (34.3 %) pts and was more prevalent in chronic DCM [17 (48.6 %) vs. 7 (20 %), p < 0.01]. The levels of PIIINP [4.41 (2.17-6.08) vs. 3.32 (1.69-5.02) ng/ml, p < 0.001], CTGF [3.82 (0.48-23.87) vs. 2.37 (0.51-25.32) ng/ml, p < 0.01], MMP-2 [6.06 (2.72-14.8) vs. 4.43 (2.27-7.4) ng/ml, p < 0.001], MMP-9 [1.98 (0.28-9.25) vs. 1.01 (0.29-3.59) ng/ml, p < 0.002)], and TIMP-1 [15.29 (1.8-36.17) vs. 2.61 (1.65-24.09) ng/ml, p < 0.004] were significantly higher in DCM, whereas levels of col-1 [57.7 (23.1-233.4) vs. 159.4 (31.2-512.9) pg/ml, p < 0.001] were significantly lower in DCM compared to controls. There were no differences in all measured serum markers of ECM metabolism between newonset and chronic DCM and as well as fibrosis positive and negative pts. Fibrosis was weakly correlated only with the duration of DCM (r = 0.23, p < 0.05), however, not a single serum marker of fibrosis correlated with fibrosis. Neither unadjusted nor adjusted models, constructed from serum markers of ECM metabolism, predicted the probability of myocardial fibrosis. Dynamics of ECM turnover in DCM is high, which is reflected by the increased levels CTGF and degradation enzymes. Synthesis of collagen type III prevailed over collagen type I. ECM metabolism was not different in DCM regardless of the duration of the disease and status of myocardial fibrosis. Serum markers of ECM metabolism were found not to be useful for the prediction of myocardial fibrosis in DCM.
引用
收藏
页码:941 / 949
页数:9
相关论文
共 29 条
[1]   Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients [J].
Batlle, M. ;
Perez-Villa, F. ;
Garcia-Pras, E. ;
Lazaro, A. ;
Orus, J. ;
Roque, M. ;
Roig, E. .
TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) :2344-2346
[2]   The role of endomyocardial biopsy in the management of cardiovascular disease - A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology [J].
Cooper, Leslie T. ;
Baughman, Kenneth L. ;
Feldman, Arthur M. ;
Frustaci, Andrea ;
Jessup, Mariell ;
Kuhl, Uwe ;
Levine, Glenn N. ;
Narula, Jagat ;
Starling, Randall C. ;
Towbin, Jeffrey ;
Virmani, Renu .
CIRCULATION, 2007, 116 (19) :2216-2233
[3]   Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases [J].
Elliott, Perry ;
Andersson, Bert ;
Arbustini, Eloisa ;
Bilinska, Zofia ;
Cecchi, Franco ;
Charron, Philippe ;
Dubourg, Olivier ;
Hl, Uwe Ku R. ;
Maisch, Bernhard ;
McKenna, William J. ;
Monserrat, Lorenzo ;
Pankuweit, Sabine ;
Rapezzi, Claudio ;
Seferovic, Petar ;
Tavazzi, Luigi ;
Keren, Andre .
EUROPEAN HEART JOURNAL, 2008, 29 (02) :270-276
[4]   Chemokines in the ischemic myocardium: from inflammation to fibrosis [J].
Frangogiannis, NG .
INFLAMMATION RESEARCH, 2004, 53 (11) :585-595
[5]   Matrix metalloproteinase-9, tissue inhibitor ofmetalloproteinase-1, B+ tenascin-C and ED-A+ fibronectin in dilated cardiomyopathy: Potential impact on disease progression and patients' prognosis [J].
Franz, Marcus ;
Berndt, Alexander ;
Neri, Dario ;
Galler, Kerstin ;
Gruen, Katja ;
Porrmann, Christiane ;
Reinbothe, Franziska ;
Mall, Gerhard ;
Schlattmann, Peter ;
Renner, Andre ;
Figulla, Hans Reiner ;
Jung, Christian ;
Kuethe, Friedhelm .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (06) :5344-5351
[6]   ECHOCARDIOGRAPHIC MEASUREMENTS IN NORMAL SUBJECTS FROM INFANCY TO OLD-AGE [J].
HENRY, WL ;
GARDIN, JM ;
WARE, JH .
CIRCULATION, 1980, 62 (05) :1054-1061
[7]   Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy [J].
Herpel, E ;
Pritsch, M ;
Koch, A ;
Dengler, TJ ;
Schirmacher, P ;
Schnabel, PA .
HISTOPATHOLOGY, 2006, 48 (06) :736-747
[8]   Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy - A pilot study [J].
Izawa, H ;
Murohara, T ;
Nagata, K ;
Isobe, S ;
Asano, H ;
Amano, T ;
Ichihara, S ;
Kato, T ;
Ohshima, S ;
Murase, Y ;
Iino, S ;
Obata, K ;
Noda, A ;
Okumura, K ;
Yokota, M .
CIRCULATION, 2005, 112 (19) :2940-2945
[9]   MEASURING EXTRACELLULAR-MATRIX TURNOVER IN THE SERUM OF PATIENTS WITH IDIOPATHIC OR ISCHEMIC DILATED CARDIOMYOPATHY AND IMPACT ON DIAGNOSIS AND PROGNOSIS [J].
KLAPPACHER, G ;
FRANZEN, P ;
HAAB, D ;
MEHRABI, M ;
BINDER, M ;
PLESCH, K ;
PACHER, R ;
GRIMM, M ;
PRIBILL, I ;
EICHLER, HG ;
GLOGAR, HD .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (14) :913-918
[10]   The effect of prolonged systemic doxycycline therapy on serum tissue degrading proteinases in coronary bypass patients: a randomized, double-masked, placebo-controlled clinical trial [J].
Kormi, Immi ;
Alfakry, Hatem ;
Tervahartiala, Taina ;
Pussinen, Pirkko J. ;
Sinisalo, Juha ;
Sorsa, Timo .
INFLAMMATION RESEARCH, 2014, 63 (05) :329-334